Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 100: Sotorasib in KRAS p.G12C-mutated advanced solid tumors and NSCLC
jRCT2080224746Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of sotorasib in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (6 arms), sponsored by Amgen. Primary endpoints: Safety and tolerability of sotorasib, Pharmacokinetics of sotorasib and 2 more. Started Jun 2019; status: completed.
02
Drugs
sotorasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224746.